NHS spending watchdog said donanemab, which would have been available to around 70,000 people in England and Wales, 'does not currently demonstrate value' for money.
NHS spending watchdog said donanemab, which would have been available to around 70,000 people in England and Wales,"does not currently demonstrate value" for money.
Donanemab, manufactured by pharmaceutical giant Eli Lilly, is not a cure but works by clearing amyloid, a hallmark of Alzheimer’s disease, from the brain slowing down the early stages of Alzheimer’s by between four and seven months. It is estimated that around 70,000 adults in England would have been eligible for treatment.
“Our independent committee looked at all the available evidence, including the benefits for carers. This shows donanemab could slow down cognitive decline by four to seven months, but this is just not enough benefit to justify the additional cost to the NHS. The cost-effectiveness estimate for donanemab is five to six times above what Nice normally considers an acceptable use of NHS resources.
Both donanemab and lecanemab bind to amyloid, a protein which builds up in the brains of people living with Alzheimer’s disease. By binding to amyloid, the drugs are designed to help clear the build-up and slow down cognitive decline. Evidence suggests that people get the most benefit if they are given the treatment at an earlier stage of the disease.
Hilary Evans-Newton, Chief Executive at Alzheimer’s Research UK, said today’s announcement “marks another frustrating setback for people affected by Alzheimer’s disease”. “We’ve written to the Health Secretary again, calling for his leadership to bring together Nice, NHS England and industry so that people with dementia in the UK aren’t left behind.”
Peter Almond completed the London to Brighton Bike Ride in June to raise money for Alzheimer’s Research UK.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Second ‘game-changing’ Alzheimer’s drug docanemab that slows disease gets green light in UK...What is the 'game-changing' Alzheimer's drug donanemab?
Read more »
Major Alzheimer's breakthrough as experts discover 'double whammy' drug that destroys memory-robbing...In video Alzheimer's Research UK explains which diseases cause dementia, how do they affect the brain and what symptoms do they lead to?
Read more »
Brazil-Italy joint lab focuses on Alzheimer’s drug developmentA self-proclaimed Brazil-Italy collaboration enthusiast, researcher Laura Bolognesi created the B2AlzD2 Joint Lab at the Department of Pharmacy and Biotechnology of the Università di Bologna (UNIBO), the first Brazil-Bologna joint laboratory dedicated to the development of new drugs for the treatment of Alzheimer's disease.
Read more »
Targeting hippocampal neurons to unlock existing Alzheimer's drugsA team of researchers at Kobe Gakuin University in Japan have genetically engineered insulin-fused proteins capable of targeting hippocampal neurons. The innovative technique capitalizes on insulin's natural tendency to accumulate in the hippocampal neuronal tissue.
Read more »
Raising money for charity is a walk in the park for Rutherglen's young and oldThe Alzheimer Scotland Memory Walk took place in Overtoun Park
Read more »
The molecular underpinnings by which traumatic brain injury increases Alzheimer's disease riskFindings indicate BAG3 modulation after traumatic brain injury may mitigate tau buildup and cognitive deficits, presenting a target for Alzheimer's prevention.
Read more »